Malaysian Company Buys $8M Stake in Synthetic Genomics | GenomeWeb
NEW YORK (GenomeWeb News) – Synthetic Genomics has sold one million shares to the Malaysian company Dragasic, a subsidiary of the Genting Group, for $8 million, Genting said today, according to the Malaysian news agency Bernama.
Genting said that the Class A common stock it purchased from Synthetic Genomics Founder, Chariman, and CEO Craig Venter represents a roughly two percent economic interest and three percent voting interest in the La Jolla, Calif.-based company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.